CARYSIL CARYSIL NSE
Company Profile ↓Company Overview
CARYSIL (CARYSIL) is a publicly traded company listed on NSE with a market capitalization of ₹3,607.09 Cr. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 16.1%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 20.2%.
Net profit has compounded at 27.0% per year over the last five years.
Revenue has grown at a 21.9% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of ₹923.95 Cr (+13.3% YoY); net profit ₹98.19 Cr.
- Trailing 12 Months Year-on-year growth — revenue +13.3%, earnings +54.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 21.9%, profit CAGR 27.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 21.95% |
| 1 Year: | 13.29% |
Compounded Profit Growth
| 5 Years: | 26.99% |
| 1 Year: | 54.05% |
Stock Price Performance
| 1 Year: | +48.43% |
| 6 Months: | +57.69% |
| 3 Months: | +42.51% |
| 1 Month: | +8.10% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.87 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 20.2%.
- Compounding revenue at 21.9% over 5 years.
- Profit CAGR of 27.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 56.6.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 146.00 Cr | 142.00 Cr | 164.00 Cr | 188.00 Cr | 191.00 Cr | 201.00 Cr | 207.00 Cr | 203.00 Cr | 204.18 Cr | 226.99 Cr | 240.67 Cr | 222.57 Cr | 233.72 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 93.63 Cr | 107.61 Cr | 115.83 Cr | 100.51 Cr | 104.44 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 110.55 Cr | 119.38 Cr | 124.84 Cr | 122.06 Cr | 129.28 Cr |
| Operating Expenses | 119.00 Cr | 116.00 Cr | 131.00 Cr | 153.00 Cr | 156.00 Cr | 165.00 Cr | 170.00 Cr | 174.00 Cr | 83.84 Cr | 84.97 Cr | 88.27 Cr | 89.40 Cr | 95.31 Cr |
| Operating Income | 19.00 Cr | 19.00 Cr | 25.00 Cr | 27.00 Cr | 26.00 Cr | 27.00 Cr | 27.00 Cr | 20.00 Cr | 26.71 Cr | 34.41 Cr | 36.57 Cr | 32.66 Cr | 33.97 Cr |
| EBITDA | 26.00 Cr | 26.00 Cr | 33.00 Cr | 35.00 Cr | 35.00 Cr | 36.00 Cr | 37.00 Cr | 29.00 Cr | 37.22 Cr | 45.11 Cr | 50.74 Cr | 43.66 Cr | 49.65 Cr |
| Interest Expense | 4.00 Cr | 5.00 Cr | 5.00 Cr | 6.00 Cr | 6.00 Cr | 6.00 Cr | 6.00 Cr | 6.00 Cr | 5.42 Cr | 5.34 Cr | 4.86 Cr | 4.74 Cr | 4.76 Cr |
| Pretax Income | 16.00 Cr | 16.00 Cr | 22.00 Cr | 22.00 Cr | 21.00 Cr | 23.00 Cr | 24.00 Cr | 18.00 Cr | 23.58 Cr | 30.33 Cr | 36.34 Cr | 29.40 Cr | 33.83 Cr |
| Tax Provision | 3.68 Cr | 4.00 Cr | 6.16 Cr | 6.82 Cr | 5.46 Cr | 6.90 Cr | 6.48 Cr | 5.58 Cr | 4.76 Cr | 7.42 Cr | 8.92 Cr | 8.14 Cr | 6.45 Cr |
| Net Income | 12.00 Cr | 12.00 Cr | 16.00 Cr | 15.00 Cr | 16.00 Cr | 16.00 Cr | 17.00 Cr | 13.00 Cr | 18.58 Cr | 22.82 Cr | 27.19 Cr | 21.08 Cr | 27.10 Cr |
| Diluted EPS | 4.64 | 4.32 | 5.76 | 5.72 | 5.79 | 5.91 | 5.91 | 4.40 | 6.53 | 8.03 | 9.56 | 7.41 | 9.52 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.00 Cr | 174.00 Cr | 181.00 Cr | 196.00 Cr | 252.00 Cr | 276.00 Cr | 310.00 Cr | - | 587.62 Cr | 679.04 Cr | 815.57 Cr | 923.95 Cr |
| Cost of Revenue | - | - | - | - | - | - | - | - | 356.75 Cr | 385.28 Cr | 377.04 Cr | 428.39 Cr |
| Gross Profit | - | - | - | - | - | - | - | - | 230.87 Cr | 293.76 Cr | 438.53 Cr | 495.56 Cr |
| Operating Expenses | 103.00 Cr | 143.00 Cr | 154.00 Cr | 169.00 Cr | 209.00 Cr | 229.00 Cr | 243.00 Cr | - | 142.93 Cr | 190.31 Cr | 337.11 Cr | 357.95 Cr |
| Operating Income | 20.00 Cr | 26.00 Cr | 21.00 Cr | 20.00 Cr | 33.00 Cr | 36.00 Cr | 54.00 Cr | - | 87.94 Cr | 103.45 Cr | 101.42 Cr | 137.61 Cr |
| EBITDA | 24.00 Cr | 31.00 Cr | 27.00 Cr | 27.00 Cr | 42.00 Cr | 48.00 Cr | 67.00 Cr | - | 108.31 Cr | 133.58 Cr | 147.15 Cr | 189.16 Cr |
| Interest Expense | 8.00 Cr | 9.00 Cr | 11.00 Cr | 8.00 Cr | 12.00 Cr | 10.00 Cr | 8.00 Cr | - | 13.86 Cr | 20.36 Cr | 23.40 Cr | 19.70 Cr |
| Pretax Income | 13.00 Cr | 18.00 Cr | 13.00 Cr | 17.00 Cr | 24.00 Cr | 30.00 Cr | 54.00 Cr | - | 68.10 Cr | 80.78 Cr | 87.85 Cr | 129.90 Cr |
| Tax Provision | 4.16 Cr | 5.76 Cr | 4.81 Cr | 4.76 Cr | 6.72 Cr | 7.50 Cr | 14.58 Cr | - | 15.27 Cr | 22.42 Cr | 23.53 Cr | 30.93 Cr |
| Net Income | 9.00 Cr | 12.00 Cr | 8.00 Cr | 12.00 Cr | 17.00 Cr | 23.00 Cr | 39.00 Cr | - | 52.42 Cr | 57.89 Cr | 63.74 Cr | 98.19 Cr |
| Diluted EPS | 3.75 | 4.21 | 2.80 | 4.61 | 6.65 | 8.27 | 14.65 | 24.13 | 19.52 | 21.55 | 22.41 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 147.00 Cr | 199.00 Cr | 233.00 Cr | 260.00 Cr | 291.00 Cr | 325.00 Cr | 391.00 Cr | - | 712.31 Cr | 844.67 Cr | 985.29 Cr | 1,042.18 Cr |
| Current Assets | - | - | - | - | - | - | - | - | 353.00 Cr | 413.84 Cr | 526.41 Cr | 521.32 Cr |
| Cash & Equivalents | - | - | - | - | - | - | - | - | 3.92 Cr | 8.74 Cr | 12.85 Cr | 7.63 Cr |
| Inventory | - | - | - | - | - | - | - | - | 130.57 Cr | 173.18 Cr | 221.14 Cr | 259.11 Cr |
| Receivables | - | - | - | - | - | - | - | - | 103.05 Cr | 137.79 Cr | 146.01 Cr | 160.74 Cr |
| Total Liabilities | - | - | - | - | - | - | - | - | 405.28 Cr | 486.55 Cr | 453.95 Cr | 427.83 Cr |
| Current Liabilities | - | - | - | - | - | - | - | - | 310.35 Cr | 354.84 Cr | 349.70 Cr | 361.68 Cr |
| Long Term Debt | - | - | - | - | - | - | - | - | 78.30 Cr | 114.66 Cr | 89.26 Cr | 47.13 Cr |
| Total Debt | 73.00 Cr | 67.00 Cr | 80.00 Cr | 92.00 Cr | 97.00 Cr | 102.00 Cr | 107.00 Cr | - | 235.02 Cr | 312.23 Cr | 276.44 Cr | 282.54 Cr |
| Total Equity | 42.00 Cr | 79.00 Cr | 112.00 Cr | 118.00 Cr | 135.00 Cr | 157.00 Cr | 191.00 Cr | - | 303.38 Cr | 354.00 Cr | 526.51 Cr | 608.42 Cr |
| Shares Outstanding | - | - | - | - | - | - | - | - | 2.68 Cr | 2.68 Cr | 2.84 Cr | 2.84 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.00 Cr | 11.00 Cr | 6.00 Cr | 16.00 Cr | 24.00 Cr | 30.00 Cr | 45.00 Cr | - | 71.16 Cr | 53.40 Cr | 60.17 Cr | 108.67 Cr |
| Investing Cash Flow | -27.00 Cr | -13.00 Cr | -14.00 Cr | -20.00 Cr | -17.00 Cr | -19.00 Cr | -35.00 Cr | - | -136.46 Cr | -97.14 Cr | -109.47 Cr | -89.20 Cr |
| Financing Cash Flow | 25.00 Cr | 19.00 Cr | 2.00 Cr | -0 | -4.00 Cr | -10.00 Cr | -9.00 Cr | - | 64.12 Cr | 48.39 Cr | 53.41 Cr | -24.69 Cr |
| Capital Expenditure | -12.00 Cr | -9.00 Cr | -13.00 Cr | -20.00 Cr | -19.00 Cr | -20.00 Cr | -35.00 Cr | - | -57.88 Cr | -93.12 Cr | -47.28 Cr | -111.49 Cr |
| Free Cash Flow | -5.00 Cr | 2.00 Cr | -7.00 Cr | -4.00 Cr | 5.00 Cr | 10.00 Cr | 10.00 Cr | - | 13.28 Cr | -39.72 Cr | 12.89 Cr | -2.82 Cr |
| Net Change in Cash | 5.00 Cr | 17.00 Cr | -6.00 Cr | -5.00 Cr | 2.00 Cr | 1.00 Cr | 2.00 Cr | - | -1.18 Cr | 4.65 Cr | 4.11 Cr | -5.22 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | 39.3% | 43.3% | 53.8% | 53.6% |
| Operating Margin % | 15.7% | 14.9% | 11.6% | 10.2% | 13.1% | 13.0% | 17.4% | - | 15.0% | 15.2% | 12.4% | 14.9% |
| Net Margin % | 7.1% | 6.9% | 4.4% | 6.1% | 6.7% | 8.3% | 12.6% | - | 8.9% | 8.5% | 7.8% | 10.6% |
| ROE % | 21.4% | 15.2% | 7.1% | 10.2% | 12.6% | 14.6% | 20.4% | - | 17.3% | 16.4% | 12.1% | 16.1% |
| ROCE % | - | - | - | - | - | - | - | - | 21.9% | 21.1% | 16.0% | 20.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CARYSIL
Earnings Not Telling The Story For Carysil Limited (NSE:CARYSIL) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZGpjY1g3ZHdmSURQdTFmQUhYcFo5SUFZQnFVNU50Q0dBVVpDRDNiWXg1TnQ5OE5QLUxXOGlqZkVBMWRjTDBfRmpmbUFRa1pNb0hlaDAyRmpBaDd0R25tZThVbmczYU14Z3hXb0xvT0QwTDNrQzdYNjZsYkY0MTRwTTd2TTNVQUl3VjQyUU…
Carysil Expands Sink Capacity; Shares Gain Over 3% - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQckhNZU9sc20tZHVFcFM5ZjFnNmNfOFdldVU0aWZFOWJ1dVhEdHRJYUtmX3NiSnNjLUJvelZ6Z3NIODNjalpJbnI0cmc3MEFmTEM2ZklpWXdfQnRSUEpPNTZMU1VwWE1XM0QyQ0oxMXlwaWJlb3VjMWJkT2VCX3pLTFZnQmNhbGhZd3RDVG…
Is Carysil your next growth stock? Anand Rathi says 'Buy', 28% upside eyed - Business Standard
<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQTTdkUlo3ZlowMTFXd1lmVDNDekhNRk9HWFNQaFlFbWpkSkRrcW9GNklTXzlpeEVNbGJqSkdRNnZSeFZMUWZsVU9mTUF5MUlsYXpnUWJaeDRzbURSTGs0czl6TWdfSktySm5CTVZSRmgxOC1DNWtudnpEMjQ5bFJjQzg2R09pRVZ6blRMUk…
Carysil shares surge 15% after Q4 profit jumps 45% on strong demand and revenue growth - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNejBNSG9NWk5fenp5QTNUSmI0RlJ0RUpYYi1aeW0yUlNKVmNNU2dzb2RoaHJHMDgwRFFwRzB3bHhGQi15d2lyc1IwcGNUSHRkYWlsSFR3cTktZEFVd1lUR3pFc09ZUlZPMFpWbW9wTmNWYXloenZVUTVla3ZIS3kzTnlweU85M08teGZiQ2…
Carysil Ltd pays ₹1.44 lakh for FEMA reporting delay - scanx.trade
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOVkdIdnI5YXlLWVpXZTMySktLUXJxN0ZJUTFRLU9VVTBocnZqM3J2WkhXaWUzVXNqRVBPNmoyZk5pcFYtTnNuOTdIaUROSEJYenlZSG9GNVVUazFIUzU4a1lheGJpdEpqbzhuTXo2dFBSOTBCSGJvYWhaSmJIdF9PQ1R3ajRodU83X09vb0…
HOT STOCKS: CARYSIL Hits All-Time High; NIACL, KPRMILL, STARHEALTH, ICIL Lead Gainers; CENTUM, VBL, NBCC, APARINDS Among Top Losers While BEL, DMART, LUPIN Climb Above 50-SMA - MarketSmith India
<a href="https://news.google.com/rss/articles/CBMiowJBVV95cUxObGhGa1dQMmM1WWR0VVJPMVFHVFBBcUlKNXhjZHdtTk91Vy1oUzRUWTdrNzlJZFhwRkdLYnYxMXFLNVMtdkh2Rkk2ellfbnN1TXlZNXNyWmYycUpXaTFtQ3RvVDdrb0ZMV3ZJbWpuM0hOXzl3djQyT0VkazllNHBRd0x0ZUVLRjhwTDFIUU…
CARYSIL — Frequently Asked Questions
What is the current share price of CARYSIL?
As of 2026-07-15 09:52 IST, CARYSIL trades at ₹1,268.20 on NSE. Its 52-week range is ₹737.05 to ₹1,268.20.
What is the market capitalisation of CARYSIL?
CARYSIL has a market capitalisation of ₹3,607.09 Cr on NSE.
What is the P/E ratio of CARYSIL?
CARYSIL trades at a trailing price-to-earnings (P/E) ratio of 56.59. Its price-to-book (P/B) ratio is 5.53.
What is the return on equity (ROE) of CARYSIL?
CARYSIL has a return on equity (ROE) of 16.14%. Its return on capital employed (ROCE) is 20.22%.
Is CARYSIL a good stock to buy?
This page provides a data-driven analysis of CARYSIL, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.